21.22
Anaptysbio Inc stock is traded at $21.22, with a volume of 1.39M.
It is up +10.01% in the last 24 hours and up +42.32% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$19.29
Open:
$19.06
24h Volume:
1.39M
Relative Volume:
1.57
Market Cap:
$645.70M
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-3.4901
EPS:
-6.08
Net Cash Flow:
$-121.61M
1W Performance:
+45.54%
1M Performance:
+42.32%
6M Performance:
-38.76%
1Y Performance:
-4.80%
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ANAB
Anaptysbio Inc
|
21.22 | 645.70M | 17.16M | -163.62M | -121.61M | -6.08 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.00 | 117.92B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
673.60 | 73.64B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
639.41 | 38.85B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
256.45 | 33.20B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
119.83 | 28.73B | 3.30B | -501.07M | 1.03B | -2.1146 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-04-25 | Initiated | Wolfe Research | Outperform |
Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
Jul-22-24 | Initiated | H.C. Wainwright | Buy |
Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
Apr-16-24 | Initiated | Leerink Partners | Outperform |
Apr-11-24 | Initiated | Wells Fargo | Overweight |
Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
Feb-26-24 | Initiated | BTIG Research | Buy |
Feb-21-24 | Initiated | Stifel | Buy |
Feb-16-24 | Initiated | Piper Sandler | Overweight |
May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
May-18-23 | Initiated | TD Cowen | Outperform |
Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
Sep-19-22 | Resumed | H.C. Wainwright | Buy |
Sep-13-22 | Downgrade | Truist | Buy → Hold |
Sep-01-22 | Initiated | Raymond James | Outperform |
Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
Jun-22-21 | Initiated | H.C. Wainwright | Buy |
May-21-21 | Initiated | UBS | Neutral |
Mar-16-21 | Upgrade | Truist | Hold → Buy |
Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
Jun-21-19 | Downgrade | Stifel | Buy → Hold |
Dec-20-18 | Initiated | H.C. Wainwright | Buy |
Nov-21-18 | Initiated | JP Morgan | Overweight |
Jul-19-18 | Initiated | Credit Suisse | Outperform |
Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Mar-27-18 | Reiterated | Stifel | Buy |
Mar-06-18 | Reiterated | Stifel | Buy |
Feb-15-18 | Reiterated | SunTrust | Buy |
Jan-23-18 | Reiterated | Credit Suisse | Outperform |
Nov-15-17 | Initiated | SunTrust | Buy |
Nov-09-17 | Initiated | Jefferies | Buy |
Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year? - MSN
AnaptysBio price target raised to $22 from $19 at H.C. Wainwright - MSN
When the Price of (ANAB) Talks, People Listen - Stock Traders Daily
Wells Fargo & Company Boosts AnaptysBio (NASDAQ:ANAB) Price Target to $51.00 - Defense World
Wells Fargo & Company Issues Positive Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
AnaptysBio (NASDAQ:ANAB) Stock Price Up 16.5%Still a Buy? - MarketBeat
What Analysts Were Expecting After AnaptysBio Inc (NASDAQ: ANAB) rose 19.44% - Stocks Register
AnaptysBio, Inc. (NASDAQ:ANAB) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected - Simply Wall St
Positive Outlook on AnaptysBio: Buy Rating Based on Undervaluation and Promising Pipeline - TipRanks
AnaptysBio (NASDAQ:ANAB) Given Outperform Rating at Wedbush - MarketBeat
H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral By Investing.com - Investing.com Canada
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data - Yahoo Finance
H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral - MSN
AnaptysBio (NASDAQ:ANAB) Receives "Outperform" Rating from Wedbush - MarketBeat
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains? - Yahoo Finance
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment - MSN
Rosnilimab shows promise in rheumatoid arthritis trial By Investing.com - Investing.com Canada
Rosnilimab shows promise in rheumatoid arthritis trial - MSN
Vanda and AnaptysBio link for generalised pustular psoriasis therapy - MSN
Anaptys stock surges on trial readout (update) (ANAB:NASDAQ) - Seeking Alpha
AnaptysBio rockets on rosnilimab data - The Pharma Letter
AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial - Yahoo Finance
AnaptysBio climbs on arthritis drug trial data - TradingView
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday - Benzinga
AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2 trial - Fierce Biotech
AnaptysBio stock soars on positive RA trial results - MSN
AnaptysBio Announces Promising Phase 2b RENOIR Trial Results - TipRanks
Anaptys Announces Rosnilimab Achieves Positive Results in Ra Phase 2B Trial and Highest Ever Reported Cdai Lda Response over 6 Months - Marketscreener.com
Anaptys surges as arthritis therapy succeeds in mid-stage trial - MSN
Anaptys stock surges on trial readout (ANAB:NASDAQ) - Seeking Alpha
AnaptysBio stock soars on positive RA trial results By Investing.com - Investing.com Australia
Anaptys Announces Rosnilimab Achieved Positive Results In RA Phase 2B Trial -February 12, 2025 at 07:44 am EST - Marketscreener.com
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months - The Manila Times
AnaptysBio announces Phase 2b RENOIR trial met primary endpoint - TipRanks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
AnaptysBio (ANAB) Stock Sees Strong Gains In Extended Session - Stocks Telegraph
Anaptys to Announce Top-line Data from Phase 2b Trial of - GlobeNewswire
AnaptysBio to Host Investor Call for Phase 2b RENOIR Trial Data of Rosnilimab in Rheumatoid Arthritis - Nasdaq
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 - Yahoo Finance
Ratio Review: Analyzing AnaptysBio Inc (ANAB)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
AnaptysBio (NASDAQ:ANAB) Upgraded by Wolfe Research to Strong-Buy Rating - MarketBeat
Wedbush Weighs in on AnaptysBio's Q1 Earnings (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Now Covered by Wolfe Research - MarketBeat
SG Americas Securities LLC Buys 4,231 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
FY2029 Earnings Estimate for AnaptysBio Issued By Wedbush - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Gap UpStill a Buy? - MarketBeat
Weekly Investment Analysts’ Ratings Updates for AnaptysBio (ANAB) - Defense World
AnaptysBio's (ANAB) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat
Wedbush Reiterates "Outperform" Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
Check Out AnaptysBio Inc (ANAB)’s Trade Data Rather Than the Analysts’ Views - SETE News
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):